Etiam partners with French healthcare network
Etiam Cooperative Medical Imaging Products signed a partnership agreement with Cegetel, a healthcare network in France, to equip all of Cegetel’s 16,000 subscribers with a basic version of
Etiam Cooperative Medical Imaging Products signed a partnership agreement with Cegetel, a healthcare network in France, to equip all of Cegetels 16,000 subscribers with a basic version of Etiams Mediem medical e-mail system, called Mediem Box, by the end of this year. This is the first commercial implementation of Mediem, a multimedia e-mail program that allows users to e-mail structured correspondence, free text notes or letters, medical imaging files, annotations, and audio messages such as dictated reports. Mediem employs Java code and is fully compatible with DICOM, according to the Rennes, France-based firm. Cegetel expects to expand its subscriber base to 50,000 this year; all new subscribers will also gain the Mediem capability.
© 2000 Miller Freeman, Inc., a United News & Media company.
- Search again
- Homepage
FDA Clears Virtually Helium-Free 1.5T MRI System from Siemens Healthineers
June 26th 2025Offering a cost- and resource-saving DryCool magnet technology, the Magnetom Flow.Ace MRI system reportedly requires 0.7 liters of liquid helium for cooling over the lifetime of the device in contrast to over 1,000 liters commonly utilized with conventional MRI platforms.
SNMMI: Botox May Facilitate Relief from Dry Mouth Side Effect of PSMA-Targeted Radiopharmaceuticals
June 25th 2025For patients being treated with radiopharmaceutical agents for metastatic prostate cancer, the combination of botulinum toxin and an anti-nausea patch led to a 30 percent reduction in PSMA uptake in the salivary glands, according to preliminary research findings presented at the SNMMI conference.
SNMMI: Can 18F-Fluciclovine PET/CT Bolster Detection of PCa Recurrence in the Prostate Bed?
June 24th 2025In an ongoing prospective study of patients with biochemical recurrence of PCa and an initial negative PSMA PET/CT, preliminary findings revealed positive 18F-fluciclovine PET/CT scans in over 54 percent of the cohort, according to a recent poster presentation at the SNMMI conference.
